Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Re medical vs business buckhenry

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Sep 02, 2022 11:32am

164 Views

Post# 34938158

RE:Re medical vs business buckhenry

canadafan... I know a great deal about the science of pela but do not see the need to blabber on and on about this. you and others on here basically regurgitate the same data over and over. I dont need to hear about 4 year old data. again, I am more interested in the financial side but does not appear this is the site.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing